Global mycoplasma testing market is expected to grow with a CAGR of approximately 13.4% during the forecast period (2016-2023). Mycoplasmas are minute free-living microorganisms. They might exist as a part of the normal flora which is found in the upper respiratory tract, throat and genitourinary tract. Mycoplasma testing is used for the diagnosis of mycoplasma infection. Mycoplasma testing comprises a collection of tests that either record antibodies in the blood or microorganism directly by culturing or identifying its genetic material (DNA) in the blood and tissue samples etc. Mycoplasma testing is most often utilized to determine infection related to mycoplasma species such as “Mycoplasma pneumoniae (M. pneumoniae)”, a causative agent of respiratory infections generally stated as "atypical pneumonia."

 The global mycoplasma testing market is primarily driven due to increasing funding for life science research activities. In FY 2017; FASEB (Federation of American Societies for Experimental Biology) recommends minimum $35.0 billion for the NIH and $7.95 billion for the NSF. The U.S. National Science Foundation (NSF) funds around 20% of total federally supported basic research performed at America's colleges and universities. Furthermore, various research grant programs were conducted for life science researches. For example: The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) supports young investigators to pursue research among different fields such as infectious diseases and clinical microbiology.  As per the research grants by the ESCMID in 2017, the higher amount granted on projects includes bacterial infections & diseases is $ 21,740.90. This increasing funding supports proper flow of research activities which increases opportunity for more advancement in the mycoplasma testing related to drug discovery for infections related to mycoplasma.

Source: OBRC Analysis

The global mycoplasma testing market segments includes application, technology and end-user. Products is further sub segmented into:

• CELL LINE TESTING
• VIRUS TESTING
• END OF PRODUCTION CELLS TESTING
• OTHER MYCOPLASMA TESTING

Technology is further segmented into:

• PCR MYCOPLASMA TESTING
• DNA STAINING MYCOPLASMA TESTING
• DIRECT ASSAY MYCOPLASMA TESTING
• INDIRECT ASSAY MYCOPLASMA TESTING 
• ENZYMATIC METHODS MYCOPLASMA TESTING 
• ELISA MYCOPLASMA TESTING MARKET
• MICROBIAL CULTURE TECHNIQUES MYCOPLASMA TESTING

End-User segment is further segmented into:

• CELL BANKS
• ACADEMIC RESEARCH INSTITUTIONS
• CONTRACT RESEARCH ORGANIZATIONS
• PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
• OTHER END-USERS

 The revenue for the above end-user segment are specific to the global mycoplasma testing market. However, the total revenue of these end-users in general has been excluded from the scope of the report.

Geographically, the global mycoplasma testing market has been segmented on the basis of four major region, which include:

• North America (U.S. & Canada)
• Asia Pacific (China, India, Japan, RoAPAC)
• Europe (UK, France, Germany, RoE)
• Rest of World

Geographically, North America accounted for major share in the mycoplasma testing market in 2016 due to increasing life science researches with large number of major life science research firms such as Charles River Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.) etc. Moreover, the growing healthcare spending across North American region is boosting the growth in the North America mycoplasma market. In 2015, National Healthcare Expenditure in the U.S. was accounted to be $3.2 trillion, which has increased from last year’s expenditure which was accounted at $3 trillion in 2014. For 2015-2025, healthcare expenditure is projected to raise by perceiving an average growth rate of about 5.8% annually. Moreover, healthcare expenditure in the U.S. is projected to grow around 1.3% faster as compared to GDP per year during 2015-2025. As a result of which, healthcare GDP is expected to account for 20.1% by 2025 and also by end of 2025, and 20% of Americans are expected  to be registered in Medicare and the program is expected to spend around $18,000 a year on an average for each beneficiary as compared to approx. $12,000 in 2015.  However, Asia Pacific is expected to be the fastest growing region during the forecast period (2016-2023) due to increasing pharmaceutical outsourcing in China, India etc. for life science researches.

The global mycoplasma testing market is segmented on the basis of application, technology, end-user and product. Based on the application segment, the mycoplasma testing market is further classified into cell line testing, virus testing, end of production cells and other applications. Based on technology, the market is further segmented into PCR, DNA staining, direct assay, indirect assay, enzymatic assay and Elisa and Microbial culture techniques. The end-user segment is further classified into Cell banks, Academic research institutions, Contract research organizations, Pharmaceutical & Biotechnology companies and other end users. According to product segment, the market is further classified into Kits & Reagents, instruments and services. Kits & reagents were accounted for the major share in 2016 due to frequent purchase of consumables regarding detection of mycoplasma for cell culture research work. Moreover, instruments are expected to witness potential growth in the forecast period due to growing presence of automated instruments regarding detection of mycoplasma which provides rapid results along with greater efficiency.

The major market players of the global mycoplasma testing market are:

• CHARLES RIVER LABORATORIES, INC.
• THERMO FISHER SCIENTIFIC INC.
• ROCHE DIAGNOSTICS
• MERCK MILLIPORE
• OTHERS

Detailed analysis of these companies provided in this report comprises: Overview, SCOT Analysis, Product Portfolio, Strategic Initiative and Strategic Analysis.

These companies using various strategies such as merger & acquisition, collaboration, partnership and product launching. For instance, SpeeDx, Thermo Fisher Partner on test for treatment-Resistant STI. SpeeDX and Thermo Fisher Scientific have entered in to a partnership on 1^st July 2017 to bring to U.S. market a molecular diagnostic test for Mycoplasma genitalium.  

Why to buy the report:

This report will:

• Provide you the business strategies adopted by market player such as  Partnership that is on 1 July 2017 between SpeeDX and Thermo Fisher Scientific.
• Provide in detail the different segments such as by products, technology, end-user which are affecting the global mycoplasma testing market.
• Provide you the patent analysis of the global mycoplasma testing market.
• Identify and understand the strength, opportunities, challenges and threat of global mycoplasma testing market.
• Provide revenues of major players of the market such as Charles River Laboratories, Inc., Thermo Fisher Scientific Inc. and others.
• Provide you various regulatory policies which are affecting the global mycoplasma testing market.

How we are different from others:

At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global mycoplasma testing market offers the longest chain of market segmentation covering major market segmentation based on products, technology and end users. The report tracks the major market trends in the global mycoplasma testing market such as increasing government support for pharmaceuticals and biotechnology industries, increasing R&D activities in life science research   and so on.  For each market segments covered in global mycoplasma testing market report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the mycoplasma testing industry, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360-degree analysis, See Saw analysis, and Porter five force model and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data. 

Key findings of the global mycoplasma testing market.

• Growth in pharmaceuticals and biotechnology sector worldwide is fueling growth in global mycoplasma testing market.
• North America is anticipated to account the largest revenue share in 2016.
• Product segment is the dominating market due to growing adoption of  kits & reagent based techniques as compared to instruments.
• Product launch is the key strategy adopted by the various market players of global mycoplasma testing market.
• PCR technique is the major segment of technique. 

1.       INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2.       MARKET OVERVIEW

2.1. GLOBAL MYCOPLASMA TESTING MARKET: EVOLUTION & TRANSITION

2.2. MARKET DEFINITION & SCOPE

2.3. INDUSTRY STRUCTURE

2.4. REGULATORY FRAMEWORK

2.5. TOTAL MARKET ANALYSIS

2.5.1.        TOP 5 FINDINGS

2.5.2.        TOP 5 OPPORTUNITY MARKETS

2.5.3.        TOP 5 COMPANIES

2.5.4.        TOP 3 COMPETITIVE STRATEGIES

2.6. ESTIMATION ANALYSIS

2.7. STRATEGIC ANALYSIS

2.7.1.        INVESTMENT VS. ADOPTION MODEL

2.7.2.        360-DEGREE INDUSTRY ANALYSIS

2.7.3.        PORTERS 5 FORCE MODEL

2.7.4.        SEE-SAW ANALYSIS

2.7.5.        CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.8. COMPETITIVE ANALYSIS

2.8.1.        KEY STRATEGIES & ANALYSIS

2.8.2.        MARKET SHARE ANALYSIS

2.8.3.        TOP COMPANY ANALYSIS

2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.9.1.        INVESTMENT OPPORTUNITIES BY REGIONS

2.9.2.        OPPORTUNITIES IN EMERGING APPLICATIONS

2.9.3.        INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3.       MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1.        INCREASING FUNDING FOR LIFE SCIENCE RESEARCH ACTIVITIES

3.1.2.        INCREASING NUMBER OF BIOTECHNOLOGY & PHARMACEUTICAL FIRMS

3.1.3.        INCREASING DEMAND FOR PCR BASED ASSAYS

3.1.4.        TECHNOLOGICAL DEVELOPMENTS

3.1.5.        INCREASING PREVALENCE OF MYCOPLASMA INFECTION ACROSS THE GLOBE

3.2. MARKET RESTRAINTS

3.2.1.        STRINGENT GOVERNMENT REGULATIONS

3.2.2.        HIGH COST ASSOCIATED WITH MYCOPLASMA TESTING

3.3. MARKET OPPORTUNITIES

3.3.1.        INCREASING HEALTHCARE EXPENDITURE IN DEVELOPING COUNTRIES

3.3.2.        GROWTH IN PHARMACEUTICAL OUTSOURCING.

3.4.   MARKET CHALLENGES

3.4.1.        LACK OF SKILLED PROFESSIONALS

4.       MARKET SEGMENTATION

4.1.GLOBAL MYCOPLASMA TESTING MARKET BY APPLICATION

4.1.1.        MARKET DEFINITION AND SCOPE

4.1.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.1.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.1.4.         OPPORTUNITY MATRIX

4.1.5.        MARKET SEGMENTATION

4.1.5.1.GLOBAL CELL LINE TESTING MARKET

4.1.5.1.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.1.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.1.3.         TOP PLAYERS & KEY PRODUCTS

4.1.5.1.4.         KEY CONCLUSIONS

4.1.5.2.GLOBAL VIRUS TESTING MARKET

4.1.5.2.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.2.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.2.3.         TOP PLAYERS & KEY PRODUCTS

4.1.5.2.4.         KEY CONCLUSIONS

4.1.5.3.GLOBAL END OF PRODUCTION CELLS TESTING MARKET

4.1.5.3.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.3.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.3.3.         TOP PLAYERS & KEY PRODUCTS

4.1.5.3.4.         KEY CONCLUSIONS

4.1.5.4.GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET

4.1.5.4.1.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.1.5.4.2.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.1.5.4.3.         TOP PLAYERS & KEY PRODUCTS

4.1.5.4.4.         KEY CONCLUSIONS

4.2.GLOBAL MYCOPLASMA TESTING MARKET BY TECHNOLOGY

4.2.1.        MARKET DEFINITION AND SCOPE

4.2.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.2.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.2.4.         OPPORTUNITY MATRIX

4.2.5.        MARKET SEGMENTATION

4.2.5.1.GLOBAL PCR MYCOPLASMA TESTING MARKET

4.2.5.1.1.      APPLICATION

4.2.5.1.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.1.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.1.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.1.5.         KEY CONCLUSIONS

4.2.5.2.GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET

4.2.5.2.1.      APPLICATION

4.2.5.2.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.2.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.2.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.2.5.         KEY CONCLUSIONS

4.2.5.3.GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET

4.2.5.3.1.      APPLICATION

4.2.5.3.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.3.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.3.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.3.5.         KEY CONCLUSIONS

4.2.5.4.GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET

4.2.5.4.1.      APPLICATION

4.2.5.4.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.4.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.4.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.4.5.         KEY CONCLUSIONS

4.2.5.5.GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET

4.2.5.5.1.      APPLICATION

4.2.5.5.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.5.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.5.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.5.5.         KEY CONCLUSIONS

4.2.5.6.GLOBAL ELISA MYCOPLASMA TESTING MARKET

4.2.5.6.1.      APPLICATION

4.2.5.6.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.6.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.6.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.6.5.         KEY CONCLUSIONS

4.2.5.7.GLOBAL MICROBIAL CULTURE TECHNIQUES MYCOPLASMA TESTING MARKET

4.2.5.7.1.      APPLICATION

4.2.5.7.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.2.5.7.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.2.5.7.4.         TOP PLAYERS & KEY PRODUCTS

4.2.5.7.5.         KEY CONCLUSIONS

4.3.GLOBAL MYCOPLASMA TESTING MARKET BY END-USER

4.3.1.        MARKET DEFINITION AND SCOPE

4.3.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.3.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.3.4.         OPPORTUNITY MATRIX

4.3.5.        MARKET SEGMENTATION

4.3.5.1.GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS

4.3.5.1.1.      APPLICATION

4.3.5.1.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.1.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.3.5.1.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.1.5.         KEY CONCLUSIONS

4.3.5.2.GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS

4.3.5.2.1.      APPLICATION

4.3.5.2.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.2.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.3.5.2.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.2.5.         KEY CONCLUSIONS

4.3.5.3.GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS

4.3.5.3.1.      APPLICATION

4.3.5.3.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.3.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.3.5.3.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.3.5.         KEY CONCLUSIONS

4.3.5.4.GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

4.3.5.4.1.      APPLICATION

4.3.5.4.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.4.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.3.5.4.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.4.5.         KEY CONCLUSIONS

4.3.5.5.GLOBAL MYCOPLASMA TESTING MARKET IN OTHER END-USERS

4.3.5.5.1.      APPLICATION

4.3.5.5.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.3.5.5.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.3.5.5.4.         TOP PLAYERS & KEY PRODUCTS

4.3.5.5.5.         KEY CONCLUSIONS

4.4.GLOBAL MYCOPLASMA TESTING MARKET BY PRODUCT

4.4.1.        MARKET DEFINITION AND SCOPE

4.4.2.        DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

4.4.3.        COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

4.4.4.         OPPORTUNITY MATRIX

4.4.5.        MARKET SEGMENTATION

4.4.5.1.GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET

4.4.5.1.1.      APPLICATION

4.4.5.1.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.4.5.1.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.4.5.1.4.         TOP PLAYERS & KEY PRODUCTS

4.4.5.1.5.         KEY CONCLUSIONS

4.4.5.2.GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET

4.4.5.2.1.      APPLICATION

4.4.5.2.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.4.5.2.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.4.5.2.4.         TOP PLAYERS & KEY PRODUCTS

4.4.5.2.5.         KEY CONCLUSIONS

4.4.5.3.GLOBAL MYCOPLASMA TESTING SERVICES MARKET

4.4.5.3.1.      APPLICATION

4.4.5.3.2.         ADOPTION SCENARIO & MARKET DETERMINANTS

4.4.5.3.3.         MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

4.4.5.3.4.         TOP PLAYERS & KEY PRODUCTS

4.4.5.3.5.         KEY CONCLUSIONS

5.       COMPETITIVE LANDSCAPE

5.1. KEY STRATEGIES

5.1.1.        LIST OF MERGERS AND ACQUISITION

5.1.2.        LIST OF JOINT VENTURES

5.1.3.        LIST OF PRODUCT LAUNCHES

5.1.4.        LIST OF PARTNERSHIPS

5.2. TOP 10 COMPANY ANALYSIS

6.       GEOGRAPHICAL ANALYSIS

6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY

6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS

6.3. OPPORTUNITY MATRIX

6.4.GLOBAL MYCOPLASMA TESTING MARKET BY REGION 2014-2023 ($ MILLION)

6.4.1.      NORTH AMERICA

6.4.1.1.  INDUSTRY ANALYSIS 2014-2023 ($ MILLION)

6.4.1.2.  TOP COUNTRY ANALYSIS

6.4.1.2.1.      U.S.

6.4.1.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.1.2.1.3.   KEY CONCLUSIONS

6.4.1.2.2.      CANADA

6.4.1.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.1.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.1.2.2.3.   KEY CONCLUSIONS

6.4.2.      EUROPE

6.4.2.1.  INDUSTRY ANALYSIS 2014-2023 ($ MILLION)

6.4.2.2.  TOP COUNTRY ANALYSIS

6.4.2.2.1.      UK

6.4.2.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.1.3.   KEY CONCLUSIONS

6.4.2.2.2.      FRANCE

6.4.2.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.2.3.   KEY CONCLUSIONS

6.4.2.2.3.      GERMANY

6.4.2.2.3.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.3.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.3.3.   KEY CONCLUSIONS

6.4.2.2.4.      SPAIN

6.4.2.2.4.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.4.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.4.3.   KEY CONCLUSIONS

6.4.2.2.5.      REST OF EUROPE

6.4.2.2.5.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.2.2.5.2.   TOP PLAYERS & KEY PRODUCTS

6.4.2.2.5.3.   KEY CONCLUSIONS

6.4.3.      ASIA PACIFIC

6.4.3.1.  INDUSTRY ANALYSIS 2014-2023 ($ MILLION)

6.4.3.2.  TOP COUNTRY ANALYSIS

6.4.3.2.1.      CHINA

6.4.3.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.1.3.   KEY CONCLUSIONS

6.4.3.2.2.      INDIA

6.4.3.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.2.3.   KEY CONCLUSIONS

6.4.3.2.3.      JAPAN

6.4.3.2.3.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.3.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.3.3.   KEY CONCLUSIONS

6.4.3.2.4.      AUSTRALIA

6.4.3.2.4.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.4.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.4.3.   KEY CONCLUSIONS

6.4.3.2.5.      REST OF ASIA PACIFIC

6.4.3.2.5.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.3.2.5.2.   TOP PLAYERS & KEY PRODUCTS

6.4.3.2.5.3.   KEY CONCLUSIONS

6.4.4.      ROW

6.4.4.1.  INDUSTRY ANALYSIS 2014-2023 ($ MILLION)

6.4.4.2.  TOP COUNTRY ANALYSIS

6.4.4.2.1.      LATIN AMERICA

6.4.4.2.1.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.4.2.1.2.   TOP PLAYERS & KEY PRODUCTS

6.4.4.2.1.3.   KEY CONCLUSIONS

6.4.4.2.2.      MIDDLE EAST & AFRICA

6.4.4.2.2.1.   MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)

6.4.4.2.2.2.   TOP PLAYERS & KEY PRODUCTS

6.4.4.2.2.3.   KEY CONCLUSIONS

7.       COMPANY PROFILES

7.1. ATCC COMPANY (U.S.)

7.1.1.        OVERVIEW

7.1.2.        PRODUCT PORTFOLIO

7.1.3.        KEY INNOVATION SECTOR

7.1.4.        STRATEGIC INITIATIVES

7.1.5.        SCOT ANALYSIS

7.1.6.        STRATEGIC ANALYSIS

7.2. BIOLOGICAL INDUSTRIES (U.S.)

7.2.1.        OVERVIEW

7.2.2.        PRODUCT PORTFOLIO

7.2.3.        KEY INNOVATION SECTOR

7.2.4.        STRATEGIC INITIATIVES

7.2.5.        SCOT ANALYSIS

7.2.6.        STRATEGIC ANALYSIS

7.3. BIONIQUE TESTING LABORATORIES, INC. (U.S.)

7.3.1.        OVERVIEW

7.3.2.        PRODUCT PORTFOLIO

7.3.3.        KEY INNOVATION SECTOR

7.3.4.        STRATEGIC INITIATIVES

7.3.5.        SCOT ANALYSIS

7.3.6.        STRATEGIC ANALYSIS

7.4. CHARLES RIVER LABORATORIES, INC. (U.S.)

7.4.1.        OVERVIEW

7.4.2.        PRODUCT PORTFOLIO

7.4.3.        KEY INNOVATION SECTOR

7.4.4.        STRATEGIC INITIATIVES

7.4.5.        SCOT ANALYSIS

7.4.6.        STRATEGIC ANALYSIS

7.5. EUROFINS SCIENTIFIC S.A. (U.S.)

7.5.1.        OVERVIEW

7.5.2.        PRODUCT PORTFOLIO

7.5.3.        KEY INNOVATION SECTOR

7.5.4.        STRATEGIC INITIATIVES

7.5.5.        SCOT ANALYSIS

7.5.6.        STRATEGIC ANALYSIS

7.6. GIBRALTAR LABORATORIES INC. (U.S.)

7.6.1.        OVERVIEW

7.6.2.        PRODUCT PORTFOLIO

7.6.3.        KEY INNOVATION SECTOR

7.6.4.        STRATEGIC INITIATIVES

7.6.5.        SCOT ANALYSIS

7.6.6.        STRATEGIC ANALYSIS

7.7. INVIVOGEN (U.S.)

7.7.1.        OVERVIEW

7.7.2.        PRODUCT PORTFOLIO

7.7.3.        KEY INNOVATION SECTOR

7.7.4.        STRATEGIC INITIATIVES

7.7.5.        SCOT ANALYSIS

7.7.6.        STRATEGIC ANALYSIS

7.8. LONZA GROUP (SWITZERLAND)

7.8.1.        OVERVIEW

7.8.2.        PRODUCT PORTFOLIO

7.8.3.        KEY INNOVATION SECTOR

7.8.4.        STRATEGIC INITIATIVES

7.8.5.        SCOT ANALYSIS

7.8.6.        STRATEGIC ANALYSIS

7.9. MERCK MILLIPORE (U.S.)

7.9.1.        OVERVIEW

7.9.2.        PRODUCT PORTFOLIO

7.9.3.        KEY INNOVATION SECTOR

7.9.4.        STRATEGIC INITIATIVES

7.9.5.        SCOT ANALYSIS

7.9.6.        STRATEGIC ANALYSIS

7.10.                  MERIDIAN BIOSCIENCE, INC. (U.S.)

7.10.1.    OVERVIEW

7.10.2.    PRODUCT PORTFOLIO

7.10.3.    KEY INNOVATION SECTOR

7.10.4.    STRATEGIC INITIATIVES

7.10.5.    SCOT ANALYSIS

7.10.6.    STRATEGIC ANALYSIS

7.11.                  MINERVA BIOLABS GMBH (GERMANY)

7.11.1.    OVERVIEW

7.11.2.    PRODUCT PORTFOLIO

7.11.3.    KEY INNOVATION SECTOR

7.11.4.    STRATEGIC INITIATIVES

7.11.5.    SCOT ANALYSIS

7.11.6.    STRATEGIC ANALYSIS

7.12.                  PROMOCELL GMBH (GERMANY)

7.12.1.    OVERVIEW

7.12.2.    PRODUCT PORTFOLIO

7.12.3.    KEY INNOVATION SECTOR

7.12.4.    STRATEGIC INITIATIVES

7.12.5.    SCOT ANALYSIS

7.12.6.    STRATEGIC ANALYSIS

7.13.                  R&D SYSTEMS, INC. (U.S.)

7.13.1.    OVERVIEW

7.13.2.    PRODUCT PORTFOLIO

7.13.3.    KEY INNOVATION SECTOR

7.13.4.    STRATEGIC INITIATIVES

7.13.5.    SCOT ANALYSIS

7.13.6.    STRATEGIC ANALYSIS

7.14.                  ROCHE DIAGNOSTICS (SWITZERLAND)

7.14.1.    OVERVIEW

7.14.2.    PRODUCT PORTFOLIO

7.14.3.    KEY INNOVATION SECTOR

7.14.4.    STRATEGIC INITIATIVES

7.14.5.    SCOT ANALYSIS

7.14.6.    STRATEGIC ANALYSIS

7.15.                  THERMO FISHER SCIENTIFIC INC. (U.S.)

7.15.1.    OVERVIEW

7.15.2.    PRODUCT PORTFOLIO

7.15.3.    KEY INNOVATION SECTOR

7.15.4.    STRATEGIC INITIATIVES

7.15.5.    SCOT ANALYSIS

7.15.6.    STRATEGIC ANALYSIS

LIST OF TABLES

1.       GLOBAL MYCOPLASMA TESTING MARKET BY APPLICATION 2014-2023 ($ MILLION)

2.       GLOBAL CELL LINE TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

3.       GLOBAL VIRUS TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

4.       GLOBAL END OF PRODUCTION CELLS TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

5.       GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

6.       GLOBAL MYCOPLASMA TESTING MARKET BY TECHNOLOGY 2014-2023 ($ MILLION)

7.       GLOBAL PCR MYCOPLASMA TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

8.       GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET  BY GEOGRAPHY 2014-2023 ($ MILLION)

9.       GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

10.    GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

11.   GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

12.   GLOBAL ELISA MYCOPLASMA TESTING MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

13.   GLOBAL MYCOPLASMA TESTING MARKET BY END-USER 2014-2023 ($ MILLION)

14.   GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS BY GEOGRAPHY 2014-2023 ($ MILLION)

15.   GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS BY GEOGRAPHY 2014-2023 ($ MILLION)

16.   GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS BY GEOGRAPHY 2014-2023 ($ MILLION)

17.   GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES BY GEOGRAPHY 2014-2023 ($ MILLION)

18.   GLOBAL MYCOPLASMA TESTING MARKET BY PRODUCT 2014-2023 ($ MILLION)

19.   GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

20.   GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

21.   GLOBAL MYCOPLASMA TESTING SERVICES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)

22.   NORTH AMERICA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

23.   EUROPE MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

24.   ASIA PACIFIC MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

25.   REST OF THE WORLD MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

 

LIST OF FIGURES

1.       GLOBAL MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

2.       GLOBAL CELL LINE TESTING MARKET 2014-2023 ($ MILLION)

3.       GLOBAL VIRUS TESTING MARKET 2014-2023 ($ MILLION)

4.       GLOBAL END OF PRODUCTION CELLS TESTING MARKET 2014-2023 ($ MILLION)

5.       GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET 2014-2023 ($ MILLION)

6.       GLOBAL PCR MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

7.       GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

8.       GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

9.       GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

10.   GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

11.   GLOBAL ELISA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

12.   GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS 2014-2023 ($ MILLION)

13.   GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

14.   GLOBAL ELISA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

15.   GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS 2014-2023 ($ MILLION)

16.   GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS 2014-2023 ($ MILLION)

17.   GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS 2014-2023 ($ MILLION)

18.   GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

19.   GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET 2014-2023 ($ MILLION)

20.   GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET 2014-2023 ($ MILLION)

21.   GLOBAL MYCOPLASMA TESTING SERVICES MARKET 2014-2023 ($ MILLION)

22.   UNITED STATES (U.S.) MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

23.   CANADA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

24.   UNITED KINGDOM (UK) MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

25.   FRANCE MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

26.   GERMANY MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

27.   SPAIN MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

28.   ROE MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

29.   INDIA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

30.   CHINA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

31.   JAPAN MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

32.   AUSTRALIA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

33.   ROAPAC MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

34.   LATIN AMERICA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

35.   MENA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

Request for Sample